

Thoracic Disease-Oriented Team

Clinical Research Treatment Flowchart

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ALK

1L

2L

UCI 21-241 (Nuvalent)
NVL-655 + ALK inhibitor

Mechanism: TKI Inhibitor
Coord: Keagan Buttigieg
Accrual: 17/25

ADVANCED/METASTATIC

Exon 18

Open to Accrual Low Accruing Pending Activation

Exon 19 del or L858R

1L

2L

UCI 22-217(Janssen)
Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI and Chemo
Coord: Richard Chang
Accrual: 5/15

UCI 22-121 (J Ints bio)
JIN-A02 Monotherapy

Mechanism: TKI
Coord: Cassie Smith
Accrual: 1/7

Exon 20

Exon 21

1L

UCI 22-217(Janssen)
Amivantamb + Lazertinib w/ or
without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI
and Chemo
Coord: Richard Chang
Accrual: 5/5

2L

Stage 1A / Adjuvant

■ Open to Accrual

■ Low Accruing

■ Pending Activation



cMET and EGFR

1L

2L

UCI 20-195 (MCLA-129)

Mechanism: Antibody Drug
Coord: Cassie Smith
Accrual: 12/20

ADVANCED/METASTATIC

1L

UCI 23-66 (Boehringer Ingelheim)

BI-1810631 Monotherapy

Mechanism: TKI
 Cord: Cassie Smith
 Accrual: 2/5

2L

UCI 19-64 (Merus N.V.)

Ph I/II Study of MCLA-128, IgG1
 Bispecific Antibody Targeting
 HER2 & HER3, in Pts w/ Solid
 Tumors

Mechanism: Antibody Targeting
 HER2 and HER3
 Cord: Celest Ramirez
 Accrual: 8/10

Exon 19


Exon 20

UCI 21-234 (AstraZeneca)

Randomized: Arm 1: T-DXD(Trastuzumab Deruxtecan) or Arm 2:
 Cisplatin or Carbo + Pemetrexed + Pembrolizumab

Mechanism: Chemotherapy
 Cord: Richard Chang
 Accrual: 1/10

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

KRAS G12C

G12A, G12D, G12R, G12S,
G12V

1L

UCI 22-30 (D3S-001-100):
D3 Bio

Mechanism: TKI
Coord: Cassie Smith
Accrual: 0/3

2L

UCI 22-88 (RMC-6291
Revolution Med)

Mechanism: TKI
Coord: Richard Chang
Accrual: 4/25

UCI 23-116 (RMC-6291
Revolution Medicine)

Mechanism: TKI
Coordinator: TBD
Accrual: 0/10

UCI 21-53 (Loxo Oncology,
Inc. LOXO-RAS-20001

Mechanism: TKI
Coord: Jenny Choe
Accrual: 7/12


UCI 18-78 (Mirati MRTX-
849)

Mechanism: TKI
Coord: Celest Ramirez
24/40

UCI 22-87 (RMC-6236
Revolution Med)

Mechanism: TKI
Coordinator: Jenny Choe
Accrual: 19/25

ADVANCED/METASTATIC

 Open to Accrual Low Accruing Pending ActivationNRG-LU007

Treatment: (Randomized) Group 1:
Atezolizumab Alone. Group 2:
Atezolizumab + Radiation

Mechanism: Immunotherapy + Radiation
Coord: Richard Chang
Accrual: 2/5

UCI 22-147-3 (Janssen Research and
Development)

Mechanism: Combination of
Amivantmab and docetaxel to treat
NSCLC
Coordinator: Stephanie Fernandez
Accrual: 0/6

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

NTRK 1-3

1L

2L

UCI 16-79 (TPX-0005)

Mechanism: TKI
Coord: Stephanie Fernandez
Accrual: 17/21

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

All Comers

3L

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROR2

1L

2L

ROS1

1L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
 Coord: Keagan Buttigieg
 Accrual: 9/16

2L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
 Coord: Keagan Buttigieg
 Accrual: 9/16

UCI 21-108 (AnHeart Therapeutics)

Mechanism: TKI or ROS1 and NTRK
 fusion proteins
 Coord: Jenny Choe
 Accrual: 2/5

Advanced / Metastatic

 Open to Accrual

 Low Accruing

 Pending Activation

1L

UCI 24-83: CB-NK +
Atezolizumab

Mechanism: PD-L1
Coord: Celest Ramirez
Accrual: 0/9

2L

UCI 23-148: CJRB-01 (oral) +
Pembrolizumab

Mechanism: Live
biotherapeutic product +
Pembrolizumab
Coord: Jenny Choe
Accrual: 1/6


■ Open to Accrual

■ Low Accruing

■ Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection
Coord: Stefanie Fernandez
Accrual: 4/82

 Open to Accrual

 Low Accruing

 Pending Activation